GO:0030097 hemopoiesis: Blood Cell Formation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030097 hemopoiesis is the biological process that generates all blood cell lineages from hematopoietic stem cells, primarily in bone marrow or kidney in adult vertebrates.
• Hemopoiesis is regulated by a network of transcription factors and cytokines that control lineage commitment and differentiation.
• The process occurs in distinct developmental waves, shifting from embryonic to fetal to adult sites.
• Dysregulation of hemopoiesis underlies leukemias, anemias, and other hematological disorders.
• Extramedullary hemopoiesis can occur in liver, spleen, or other tissues when bone marrow fails.
• Hepatocyte growth factor and other microenvironmental signals modulate hematopoietic activity.
Description
Hemopoiesis, also known as hematopoiesis, is the biological process responsible for the continuous production of all blood cell types throughout an organism's life. This process ensures the replenishment of short-lived cells such as erythrocytes, granulocytes, and platelets, and provides the lymphoid cells essential for adaptive immunity. The site of hemopoiesis varies during development, beginning in the yolk sac and shifting to the liver and spleen, and finally to the bone marrow in adult vertebrates. In some vertebrates, the kidney serves as a primary hematopoietic organ. Understanding hemopoiesis is fundamental to stem cell biology, immunology, and clinical hematology, as its disruption leads to severe diseases including leukemia and bone marrow failure. Research into hemopoiesis has been driven by the need to dissect the molecular controls that govern self-renewal, proliferation, and differentiation of hematopoietic stem and progenitor cells. The process is influenced by stochastic effects and deterministic signals, and its regulation involves a complex interplay of transcription factors, growth factors, and microenvironmental cues.
hemopoiesis At A Glance
| GO ID | GO:0030097 |
|---|---|
| GO term | hemopoiesis |
| Ontology | biological_process |
| Synonym | blood cell biosynthesis, blood cell formation, haemopoiesis, hematopoiesis |
| Major function | Production of all blood cell lineages from hematopoietic stem cells |
| Site of action | Bone marrow or kidney in adult vertebrates; variable during development |
| Key cell types | Erythrocytes, granulocytes, lymphocytes, monocytes, platelets |
| Regulatory factors | Transcription factors, cytokines, growth factors, microenvironment |
What Is GO:0030097?
According to the Gene Ontology, GO:0030097 hemopoiesis is defined as the process whose specific outcome is the progression of the myeloid and lymphoid derived organ/tissue systems of the blood and other parts of the body over time, from formation to the mature structure. The site of hemopoiesis is variable during development, but occurs primarily in bone marrow or kidney in many adult vertebrates. In simpler terms, it is the entire developmental program that produces blood cells and the tissues that support them.
Why Is hemopoiesis Important in Cell Biology?
Hemopoiesis is essential for oxygen transport, immune defense, and hemostasis, and its failure or dysregulation causes a wide range of human diseases, including leukemias, lymphomas, anemias, and myelodysplastic syndromes. Because hematopoietic stem cells are the source of all blood cells, understanding hemopoiesis is critical for developing stem cell therapies, bone marrow transplantation, and targeted treatments for blood cancers. Moreover, the process serves as a paradigm for studying tissue-specific stem cell differentiation and the interplay between intrinsic genetic programs and extrinsic signals.
• Provides the foundation for understanding blood cell development and regeneration.
• Key to deciphering the molecular basis of leukemias and lymphomas.
• Informs bone marrow transplantation and stem cell therapy.
• Reveals how transcription factors control lineage commitment.
• Highlights the role of the microenvironment in stem cell regulation.
• Explains extramedullary hemopoiesis in pathological conditions.
• Relevant to anemia and cytopenia research.
• Model for studying stochastic versus deterministic cell fate decisions.
• Links developmental biology with adult tissue homeostasis.
• Supports drug discovery targeting hematopoietic pathways.
What Happens During hemopoiesis?
Embryonic and Fetal Hemopoiesis
In simple terms: Blood cell production starts in the embryo and moves to different organs as the fetus grows.
During embryonic development, hemopoiesis begins in the yolk sac and then shifts to the liver and spleen, before finally settling in the bone marrow. This developmental progression ensures a continuous supply of blood cells as the organism grows. The site of hemopoiesis is variable, and in many adult vertebrates, the bone marrow or kidney becomes the primary site.
Hematopoietic Stem Cell Self-Renewal and Differentiation
In simple terms: Stem cells can either make more of themselves or turn into specialized blood cells.
Hematopoietic stem cells (HSCs) reside in the bone marrow and possess the capacity for self-renewal and multilineage differentiation. The balance between self-renewal and differentiation is controlled by both intrinsic factors, such as transcription factors, and extrinsic cues from the microenvironment. Stochastic effects also contribute to cell fate decisions within the HSC pool.
Lineage Commitment and Maturation
In simple terms: Stem cells gradually become specific types of blood cells through a series of steps.
HSCs give rise to multipotent progenitors that progressively commit to myeloid or lymphoid lineages. This commitment is driven by the coordinated expression of lineage-specific transcription factors and is influenced by cytokines and growth factors. The mature cells, including erythrocytes, granulocytes, lymphocytes, and platelets, are then released into the circulation.
Regulation by the Microenvironment
In simple terms: The surroundings of stem cells, including other cells and signals, control their behavior.
The bone marrow microenvironment, or niche, provides essential signals that regulate HSC quiescence, proliferation, and differentiation. Hepatocyte growth factor (HGF) is one such factor that has been shown to play a role in hemopoiesis. Disruption of the niche can lead to extramedullary hemopoiesis, where blood cell production occurs outside the bone marrow.
Key Genes Involved in GO:0030097 hemopoiesis
The following genes and proteins are central to the regulation and execution of hemopoiesis, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RUNX1 | Master transcription factor for hematopoietic stem cell emergence | Studied in leukemia and stem cell development |
| TAL1 | Transcription factor involved in erythroid and megakaryocytic differentiation | Implicated in T-cell acute lymphoblastic leukemia |
| GATA1 | Key regulator of erythroid and megakaryocytic lineage commitment | Mutations cause anemias and thrombocytopenia |
| GATA2 | Essential for hematopoietic stem cell maintenance and proliferation | Haploinsufficiency leads to immunodeficiency |
| PU.1 (SPI1) | Transcription factor for myeloid and lymphoid development | Role in leukemia and immune disorders |
| CEBPA | Controls granulocytic differentiation | Mutations associated with acute myeloid leukemia |
| MYB | Regulates hematopoietic progenitor proliferation | Oncogene in leukemias |
| KIT | Receptor tyrosine kinase for stem cell factor | Mutations in mastocytosis and leukemia |
| FLT3 | Receptor tyrosine kinase regulating HSC survival | Frequently mutated in AML |
| JAK2 | Cytokine signaling kinase | V617F mutation in myeloproliferative neoplasms |
| HGF | Growth factor modulating hemopoiesis | Studied for its role in hematopoietic support |
| IL3 | Cytokine promoting multilineage progenitor growth | Used in culture and therapy |
| GM-CSF (CSF2) | Stimulates granulocyte and macrophage production | Clinical use in neutropenia |
| EPO | Hormone driving erythropoiesis | Therapeutic for anemia |
| TPO | Regulates megakaryopoiesis and platelet production | Used to treat thrombocytopenia |
| SCF (KITLG) | Stem cell factor supporting HSC survival | Essential for stem cell culture |
| CXCL12 | Chemokine maintaining HSC in bone marrow niche | Target for stem cell mobilization |
How Is hemopoiesis Regulated?
Hemopoiesis is tightly regulated by a combination of cell-intrinsic transcription factors and extrinsic signals from the bone marrow microenvironment. Cytokines such as erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor control the survival, proliferation, and differentiation of specific lineages. Hepatocyte growth factor has been shown to modulate hematopoietic activity, and its receptor, MET, is expressed on hematopoietic cells. Stochastic effects also influence cell fate decisions within the stem cell pool. Additionally, ethanol has been reported to affect hemopoiesis, highlighting the sensitivity of the process to external factors.
hemopoiesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RUNX1 | Acute myeloid leukemia, familial platelet disorder | Knockout or point-mutation in hematopoietic stem cells |
| GATA2 | Immunodeficiency, myelodysplastic syndrome | Knock-in of patient mutations in cell lines |
| JAK2 | Myeloproliferative neoplasms | Point mutation (V617F) knock-in in mice or cell lines |
| CEBPA | Acute myeloid leukemia | Knockout in myeloid progenitor cells |
| HGF | Role in hemopoiesis and tissue regeneration | Overexpression or knockout in stromal cells |
Leukemia and Lymphoma
Leukemias arise from the malignant transformation of hematopoietic progenitors, leading to uncontrolled proliferation and blocked differentiation. The molecular control of hemopoiesis is often disrupted in leukemia, with mutations in transcription factors such as RUNX1, CEBPA, and GATA2. Understanding normal hemopoiesis provides a framework for identifying the genetic lesions that drive leukemogenesis.
Anemia and Bone Marrow Failure
Anemias result from defective erythropoiesis, which can be caused by mutations in genes like GATA1 or by deficiencies in erythropoietin. Bone marrow failure syndromes, including aplastic anemia, involve the loss of hematopoietic stem cells and impaired hemopoiesis. Ethanol consumption has been linked to altered hemopoiesis, contributing to anemia in some cases.
Extramedullary Hemopoiesis
When bone marrow function is compromised, hemopoiesis can occur in extramedullary sites such as the liver, spleen, or lymph nodes, a condition known as extramedullary hemopoiesis. This compensatory mechanism is often seen in myelofibrosis and other bone marrow disorders. Imaging and histological studies are important for diagnosing this condition.
From hemopoiesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate HSC self-renewal? | Knockout in hematopoietic stem cells followed by transplantation |
| Does a point mutation in gene Y alter differentiation? | Point-mutation knock-in in cell lines or primary cells |
| What is the effect of gene Z overexpression on lineage bias? | Overexpression in hematopoietic progenitors |
| Where is protein X localized in hematopoietic cells? | Tagged knock-in with fluorescent protein |
| Which genes are essential for erythropoiesis? | CRISPR library screening in erythroid cell lines |
| How does a mutation affect cytokine signaling? | Knock-in of mutant allele and phospho-flow analysis |
How to Study the hemopoiesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression | Identifying transcriptional networks in HSCs |
| Single-cell RNA-seq | Transcriptomes of individual cells | Studying heterogeneity in hematopoietic progenitors |
| CFU assay | Clonogenic potential | Assessing differentiation capacity of progenitors |
| Flow cytometry | Surface marker expression | Isolating and quantifying blood cell subsets |
| ELISA | Cytokine concentrations | Measuring erythropoietin or HGF levels |
| Immunohistochemistry | Protein localization in tissues | Detecting extramedullary hemopoiesis |
| CRISPR screening | Gene function at scale | Identifying regulators of blood cell development |
Transcriptional Profiling
RNA sequencing (RNA-seq) is widely used to analyze gene expression changes during hemopoiesis, revealing transcription factor networks and lineage-specific signatures. Single-cell RNA-seq allows dissection of heterogeneity within hematopoietic populations.
Functional Assays
Colony-forming unit (CFU) assays and long-term culture-initiating cell (LTC-IC) assays measure the proliferative and differentiation potential of hematopoietic progenitors. These assays are essential for evaluating the impact of genetic perturbations on hemopoiesis.
Flow Cytometry and Imaging
Flow cytometry using surface markers (e.g., CD34, CD38) enables the isolation and quantification of distinct hematopoietic subsets. Imaging techniques, such as immunohistochemistry, are used to visualize extramedullary hemopoiesis in tissues.
Cytokine and Growth Factor Analysis
Enzyme-linked immunosorbent assays (ELISAs) and cytokine arrays quantify factors like erythropoietin, thrombopoietin, and HGF that regulate hemopoiesis. These methods help link microenvironmental signals to hematopoietic output.
How CRISPR Can Be Used to Study GO:0030097 hemopoiesis
Knockout
CRISPR knockout is used to ablate candidate genes in hematopoietic stem and progenitor cells to assess their requirement for self-renewal, proliferation, and differentiation. For example, knocking out RUNX1 or GATA2 in HSCs impairs their function and lineage output.
Point Mutation
Point mutations, such as JAK2 V617F, can be introduced using CRISPR base editing or homology-directed repair to model myeloproliferative neoplasms and study signaling alterations. These models help dissect the contribution of specific mutations to disease phenotypes.
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) or epitope tags allows tracking of specific hematopoietic lineages and protein localization. This approach is valuable for studying gene expression dynamics during hemopoiesis.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can be used to study the effects of increased gene dosage on hematopoietic differentiation. Overexpression of HGF, for instance, can enhance hematopoietic support in stromal cells.
How EDITGENE Supports hemopoiesis Research
Researchers studying hemopoiesis-related genes often need to determine whether a candidate gene is causally involved in blood cell development, and CRISPR-based models provide a robust way to test this. EDITGENE offers a comprehensive suite of services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for hemopoiesis research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Meis1 Knockout TM4 Cell Line | EDJ-KQ78174 | Mouse | 17268 | Details Get a Quote |
| DLL1 Knockout HEK293 Cell Line | EDJ-KQ415 | Human | 28514 | Details Get a Quote |
| JAG1 Knockout HEK293 Cell Line | EDJ-KQ427 | Human | 182 | Details Get a Quote |
| NOTCH2 Knockout HEK293 Cell Line | EDJ-KQ436 | Human | 4853 | Details Get a Quote |
| NOTCH4 Knockout HEK293 Cell Line | EDJ-KQ439 | Human | 4855 | Details Get a Quote |
| IL7R Knockout HEK293 Cell Line | EDJ-KQ502 | Human | 3575 | Details Get a Quote |
| TEK Knockout HEK293 Cell Line | EDJ-KQ759 | Human | 7010 | Details Get a Quote |
| MKNK2 Knockout HEK293 Cell Line | EDJ-KQ907 | Human | 2872 | Details Get a Quote |
| CDK13 Knockout HEK293 Cell Line | EDJ-KQ1111 | Human | 8621 | Details Get a Quote |
| RUNX2 Knockout HEK293 Cell Line | EDJ-KQ1139 | Human | 860 | Details Get a Quote |
| FLCN Knockout HEK293 Cell Line | EDJ-KQ1150 | Human | 201163 | Details Get a Quote |
| PDGFB Knockout HEK293 Cell Line | EDJ-KQ1198 | Human | 5155 | Details Get a Quote |
| TAL1 Knockout HEK293 Cell Line | EDJ-KQ1647 | Human | 6886 | Details Get a Quote |
| CD34 Knockout HEK293 Cell Line | EDJ-KQ2227 | Human | 947 | Details Get a Quote |
| RUNX1 Knockout HEK293 Cell Line | EDJ-KQ2234 | Human | 861 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »
Frequently Asked Questions About hemopoiesis
What is hemopoiesis?
Hemopoiesis is the biological process that produces all blood cells from hematopoietic stem cells, primarily in the bone marrow or kidney in adult vertebrates.
What genes are involved in hemopoiesis?
Key genes include RUNX1, GATA1, GATA2, TAL1, PU.1, CEBPA, MYB, KIT, FLT3, JAK2, and cytokines such as erythropoietin and thrombopoietin.
What is the GO term for hemopoiesis?
The Gene Ontology term for hemopoiesis is GO:0030097, under the biological_process aspect.
Where does hemopoiesis occur?
During development, hemopoiesis occurs in the yolk sac, liver, and spleen; in adult vertebrates, it primarily occurs in the bone marrow or kidney.
How is hemopoiesis regulated?
It is regulated by transcription factors, cytokines, growth factors, and the bone marrow microenvironment, with additional stochastic effects.
What diseases are associated with defective hemopoiesis?
Leukemias, lymphomas, anemias, myelodysplastic syndromes, and bone marrow failure are linked to disrupted hemopoiesis.
What is extramedullary hemopoiesis?
Extramedullary hemopoiesis is the production of blood cells outside the bone marrow, often in the liver or spleen, when bone marrow function is impaired.
How can CRISPR be used to study hemopoiesis?
CRISPR can create knockout, point mutation, knock-in, or overexpression models in hematopoietic cells to test gene function and model diseases.
What methods are used to study hemopoiesis?
Common methods include RNA-seq, flow cytometry, colony-forming assays, ELISA, and CRISPR screening.
Why is hemopoiesis important for cancer research?
Many blood cancers arise from dysregulated hemopoiesis, so understanding normal development helps identify therapeutic targets.
Conclusion
Hemopoiesis (GO:0030097) is a fundamental biological process that sustains blood cell production throughout life. Its intricate regulation by transcription factors, cytokines, and the microenvironment ensures a balanced output of diverse blood lineages. Disruption of hemopoiesis leads to a spectrum of hematological diseases, making it a critical area of research. Advances in CRISPR-based models and high-throughput methods continue to unravel the molecular mechanisms governing this process, offering hope for new therapies.
References
- 1. Orphanidou-Vlachou E et al.. 2014. Extramedullary hemopoiesis.. Semin Ultrasound CT MR 35(3):255-62 PMID: 24929265
- 2. Unknown. 1968. Ethanol and hemopoiesis.. Nutr Rev 26(10):301-5 PMID: 4880905
- 3. Barreda DR et al.. 2001. Transcriptional regulation of hemopoiesis.. Dev Comp Immunol 25(8-9):763-89 PMID: 11602195
- 4. Gordon MY et al.. 1994. Stochastic effects in hemopoiesis.. Stem Cells 12(2):175-9 PMID: 8199560
- 5. Tavassoli M. 1991. Embryonic and fetal hemopoiesis: an overview.. Blood Cells 17(2):269-81; discussion 282-6 PMID: 1912596
- 6. Till JE et al.. 1976. Cellular subclasses in human leukemic hemopoiesis.. Hamatol Bluttransfus 19:33-45 PMID: 64380
- 7. Sachs L. 1993. The molecular control of hemopoiesis and leukemia.. C R Acad Sci III 316(9):871-91 PMID: 8076216
- 8. Ikehara S. 1996. Role of hepatocyte growth factor in hemopoiesis.. Leuk Lymphoma 23(3-4):297-303 PMID: 9031110
